Samsara Therapeutics

Executive Summary

Samsara Therapeutics is a privately held, pre-clinical biotechnology company founded in 2019 with R&D operations in Oxford, UK and corporate headquarters in Boston, MA. The company is pioneering small molecule therapeutics that activate autophagy to combat age-related neurodegenerative diseases, including ALS, Parkinson's disease, and Charcot-Marie-Tooth disease. Autophagy is a cellular recycling process that declines with age, and its restoration is a promising therapeutic strategy to delay disease progression. Samsara's platform leverages deep expertise in autophagy biology and medicinal chemistry to identify novel compounds. The company is currently in the pre-clinical stage, advancing its lead candidates toward IND-enabling studies. While no financial or valuation data is publicly available, the company's focus on high-unmet-need indications and a mechanism of action with broad applicability positions it as an interesting player in the neurodegenerative disease space. However, the pre-clinical stage implies significant technical and regulatory risk, and the company will require substantial capital to reach clinical proof-of-concept.

Upcoming Catalysts (preview)

• Q4 2026Lead Candidate IND Filing with FDA40% success
• H2 2026Series A or Series B Financing Round60% success
• Q3 2026Presentation of Preclinical Data at Major Conference70% success